Distinguished in Throat Cancer

Dr. Zujun Li

Oncology | Hematology
New York University
111 Broadway, 
New York, NY 
Offers Telehealth
Distinguished in Throat Cancer
New York University
111 Broadway, 
New York, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Zujun Li is an Oncologist and a Hematologist in New York, New York. Dr. Li is rated as a Distinguished provider by MediFind in the treatment of Throat Cancer. His top areas of expertise are Laryngeal Cancer, Throat Cancer, Glioma, and Colorectal Cancer.

His clinical research consists of co-authoring 32 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 1 clinical trial in the study of Throat Cancer.

Specialties
Oncology
Hematology
Licenses
Internal Medicine in NY
Hospital Affiliations
Nyu Langone Hospitals
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CenterLight Healthcare
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health First
  • HMO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MetroPlus Health
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

NEW YORK UNIVERSITY
111 Broadway, New York, NY 10006
Other Locations
NEW YORK UNIVERSITY
560 1st Ave, New York, NY 10016
NEW YORK UNIVERSITY
160 E 34th St, New York, NY 10016

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Birinapant and Intensity Modulated Re-Irradiation Therapy (IMRRT) for Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)
Birinapant and Intensity Modulated Re-Irradiation Therapy (IMRRT) for Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)
Enrollment Status: Active_not_recruiting
Publish Date: November 07, 2025
Intervention Type: Procedure, Drug, Radiation
Study Drug: Birinapant
Study Phase: Phase 1
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Enrollment Status: Completed
Publish Date: September 23, 2025
Intervention Type: Other, Biological, Radiation
Study Drugs: Cetuximab, Durvalumab
Study Phase: Phase 2/Phase 3
A Phase I/II, Open-label, Two Part Study of GSK3359609 in Combination With Tremelimumab in Participants With Selected, Advanced Solid Tumors
A Phase I/II, Open-label, Two Part Study of GSK3359609 in Combination With Tremelimumab in Participants With Selected, Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: August 28, 2024
Intervention Type: Drug
Study Drugs: Feladilimab, Tremelimumab, Docetaxel, Paclitaxel, Cetuximab
Study Phase: Phase 1/Phase 2
A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Enrollment Status: Terminated
Publish Date: July 10, 2024
Intervention Type: Drug
Study Drugs: Feladilimab, Pembrolizumab
Study Phase: Phase 3
A Phase II, Open-label, Randomized Controlled Study of PDR001 in Patients With Moderately Differentiated/Undifferentiated Locally Advanced Recurrent or Metastatic Nasopharyngeal Carcinoma Who Progressed on Standard Treatment
A Phase II, Open-label, Randomized Controlled Study of PDR001 in Patients With Moderately Differentiated/Undifferentiated Locally Advanced Recurrent or Metastatic Nasopharyngeal Carcinoma Who Progressed on Standard Treatment
Enrollment Status: Completed
Publish Date: February 10, 2022
Intervention Type: Drug
Study Drug: PDR001
Study Phase: Phase 2
View 4 Less Clinical Trials

32 Total Publications

Implementing the NYU Electronic Patient Visit Assessment (ePVA)© for head and neck cancer in rural and urban populations: a study protocol for a type 1 hybrid effectiveness-implementation clinical trial.
Implementing the NYU Electronic Patient Visit Assessment (ePVA)© for head and neck cancer in rural and urban populations: a study protocol for a type 1 hybrid effectiveness-implementation clinical trial.
Journal: Trials
Published: January 12, 2025
Similar Doctors
Distinguished in Throat Cancer
Dr. Missak Haigentz
Oncology
Distinguished in Throat Cancer
Dr. Missak Haigentz
Oncology

Rutgers Health-Rwj Scleroderma Program

195 Little Albany St, 
New Brunswick, NJ 
 (27.2 miles away)
732-235-2465
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Missak Haigentz is an Oncologist in New Brunswick, New Jersey. Dr. Haigentz is rated as a Distinguished provider by MediFind in the treatment of Throat Cancer. His top areas of expertise are Lung Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), Throat Cancer, and Laryngeal Cancer. Dr. Haigentz is currently accepting new patients.

Advanced in Throat Cancer
Dr. Bruce E. Culliney
Hematology Oncology | Hematology | Pain Medicine
Advanced in Throat Cancer
Dr. Bruce E. Culliney
Hematology Oncology | Hematology | Pain Medicine

Icahn School Of Medicine At Mount Sinai

10 Union Sq E, 
New York, NY 
 (2.1 miles away)
212-844-8288
Languages Spoken:
English
See accepted insurances

Bruce Culliney is a Hematologist Oncology specialist and a Hematologist in New York, New York. Dr. Culliney is rated as a Distinguished provider by MediFind in the treatment of Throat Cancer. His top areas of expertise are Tongue Cancer, Throat Cancer, Laryngeal Cancer, and Nasopharyngeal Carcinoma.

Advanced in Throat Cancer
Dr. Loren S. Michel
Oncology
Advanced in Throat Cancer
Dr. Loren S. Michel
Oncology

Memorial Solid Tumor Group

530 E 74th St, 
New York, NY 
 (5.1 miles away)
212-639-2000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Loren Michel is an Oncologist in New York, New York. Dr. Michel is rated as a Distinguished provider by MediFind in the treatment of Throat Cancer. His top areas of expertise are Head and Neck Squamous Cell Carcinoma (HNSCC), Polymorphous Low Grade Adenocarcinoma, Adenoid Cystic Carcinoma, and Epithelial-Myoepithelial Carcinoma. Dr. Michel is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Li's expertise for a condition
ConditionClose
    View All 7 Distinguished Conditions
    View All 36 Advanced Conditions
    View All 66 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile